Glucagon Market Size & Growth Forecast 2027–2036, By Segments (Product Type, Distribution Channel, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Glucagon Market size was assessed at USD 476.76 Million in 2026 and is poised to grow at 6.89% CAGR between 2027 and 2036, reaching USD 928.26 Million by 2036. The industry revenue for 2027 is calculated at USD 504.65 Million.

• Base Year Value (2026): USD 476.76 Million
• CAGR (2027-2036): 6.89%
• Forecast Year Value (2036): USD 928.26 Million
• Historical Data Period: 2022-2026
• Largest Region: North America
• Forecast Period: 2027-2036

Glucagon Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America leads due to well-developed healthcare infrastructure, high awareness of severe hypoglycemia, and strong access to emergency diabetes management therapies.
  • Asia Pacific is expected to grow fastest as diabetes burden, healthcare accessibility, modern diabetes treatments, and awareness of hypoglycemia management increase.

• Segment Momentum:

  • Hypoglycemia leads the market because glucagon is a critical emergency treatment for severe low blood glucose, with increasing awareness and wider access to rescue therapies supporting sustained demand.
  • The gastrointestinal disorders segment is expanding as glucagon is increasingly used during diagnostic imaging and endoscopic procedures to temporarily relax gastrointestinal smooth muscle and improve procedural outcomes.

• Market Expansion Drivers:

  • Rising global diabetes prevalence increasing demand for emergency glucagon therapies
  • Advancements in drug delivery systems improving usability and adoption of glucagon products
  • Increased R&D investment accelerating innovation in next-generation metabolic disorder treatments

• Leading Market Participants:

  Prominent companies in the glucagon market include Eli Lilly and Company (United States), Novo Nordisk A/S (Denmark), Xeris Biopharma Holdings (United States), Zealand Pharma A/S (Denmark), Fresenius Kabi (Germany), Amphastar Pharmaceuticals (United States), Hanmi Pharmaceutical Co., Ltd. (South Korea), Lupin Limited (India), Sanofi (France), Sandoz Group AG (Switzerland)

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 476.76 Million
  • 2027 Estimated Market Size: USD 504.65 Million
  • Projected Market Size: USD 928.26 Million by 2036
  • Growth Forecasts: 6.89% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Injectable (Product Type) | Hospital Pharmacies (Distribution Channel) | Hypoglycemia (Application)
  • Emerging Opportunity Segment: Inhalation (Product Type) | Online Pharmacies (Distribution Channel) | Gastrointestinal Disorders (Application)

Market Growth Drivers and Industry Trends

Rising global diabetes prevalence increasing demand for emergency glucagon therapies

The growing incidence of diabetes across both developed and emerging economies is creating sustained demand for rapid-response treatments that address severe hypoglycemic events. The glucagon market will drive growth as healthcare providers, caregivers, and patients increasingly prioritize emergency preparedness for individuals using intensive insulin therapy. Rising awareness of hypoglycemia risks has encouraged broader prescribing practices, while clinical guidelines emphasizing timely intervention have supported the inclusion of glucagon products in diabetes management plans. Expanding access to diabetes care services, improved diagnosis rates, and greater education on recognizing hypoglycemic emergencies are also encouraging wider availability of emergency glucagon therapies across hospitals, pharmacies, and home-care settings.

Advancements in drug delivery systems improving usability and adoption of glucagon products

Innovations in administration technologies are removing many of the practical barriers that historically limited emergency glucagon use during critical situations. By simplifying preparation and reducing the complexity associated with traditional formulations, the glucagon market is benefiting from greater acceptance among caregivers, family members, educators, and first responders who may have limited medical training. User-friendly delivery formats improve confidence in emergency administration, reduce the likelihood of dosing errors, and enhance treatment accessibility outside clinical environments. These improvements also encourage healthcare professionals to recommend glucagon products more routinely as part of comprehensive diabetes emergency preparedness strategies.

Increased R&D investment accelerating innovation in next-generation metabolic disorder treatments

Expanding research activity in metabolic diseases is broadening scientific understanding of glucagon biology and creating opportunities for the development of more advanced therapeutic approaches. Increased investment from pharmaceutical developers and research institutions will propel the glucagon market growth by supporting the discovery of improved formulations, combination therapies, and novel treatment concepts that address unmet clinical needs. Continuous innovation is also strengthening development pipelines focused on improving product stability, therapeutic effectiveness, and patient convenience while expanding the potential applications of glucagon-based therapies across a wider range of metabolic conditions.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising global diabetes prevalence increasing demand for emergency glucagon therapies	2.5%	High	North America, Europe	High	Near Term
Advancements in drug delivery systems improving usability and adoption of glucagon products	2.2%	High	Europe, Asia Pacific	Medium	Mid Term
Increased R&D investment accelerating innovation in next-generation metabolic disorder treatments	2.1%	High	North America, Europe	Medium	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America dominated the glucagon market in 2026, owing to well-developed healthcare infrastructure, high awareness of severe hypoglycemia, and greater access to emergency diabetes management therapies. The region's established healthcare systems support the diagnosis and treatment of diabetes and facilitate the adoption of glucagon products for emergency use. Increasing emphasis on patient safety and preparedness for hypoglycemic episodes also contributes to sustained demand for readily accessible glucagon therapies.

Asia Pacific is expected to be the fastest-growing region over the forecast period, supported by the rising burden of diabetes, improving healthcare accessibility, and growing awareness of hypoglycemia management. Expanding healthcare infrastructure and increasing availability of modern diabetes treatments are enabling more patients to receive appropriate emergency care. Greater awareness among patients, caregivers, and healthcare professionals regarding the importance of timely treatment for severe hypoglycemia is also expected to strengthen the adoption of glucagon products across the region.

No card data available for this language/report.

Segment Leadership and Growth Trends

 

Product Type Segment Analysis: Injectable (Largest Segment) vs Inhalation (Fastest-Growing Segment)

The injectable segment held the largest share of the glucagon market in 2026. Injectable glucagon has long been established as the standard emergency treatment for severe hypoglycemia due to its proven clinical effectiveness and widespread availability across healthcare settings. Strong physician familiarity, well-defined treatment protocols, and broad integration into emergency care practices have reinforced the segment's leading position.

The inhalation segment is expected to experience the fastest growth as demand increases for non-invasive treatment options that improve patient convenience and simplify administration. Needle-free delivery methods can enhance user acceptance while reducing barriers associated with injectable therapies. Continued innovation in drug delivery technologies and growing emphasis on improving emergency treatment accessibility are expected to support rapid expansion of this segment.

Distribution Channel Segment Analysis: Hospital Pharmacies (Largest Segment) vs Online Pharmacies (Fastest-Growing Segment)

The glucagon market was led by the hospital pharmacies segment in 2026. Hospital pharmacies play a critical role in ensuring immediate availability of glucagon for emergency management of severe hypoglycemia and other clinical applications. Their integration with inpatient and emergency care services, along with established procurement systems and clinical oversight, has supported the segment's market leadership.

The online pharmacies segment is projected to witness the fastest growth due to increasing consumer preference for convenient medicine purchasing and home delivery services. Expanding digital healthcare platforms, improved accessibility to prescription medications, and greater adoption of telehealth services are encouraging more patients to obtain glucagon through online distribution channels. These trends are expected to strengthen the segment's growth over time.

Application Segment Analysis: Hypoglycemia (Largest Segment) vs Gastrointestinal Disorders (Fastest-Growing Segment)

The hypoglycemia segment represented the largest application in the glucagon market in 2026. Glucagon remains a critical therapy for the emergency treatment of severe hypoglycemia, particularly among individuals with diabetes who require rapid restoration of blood glucose levels. Increasing awareness of emergency preparedness and broader access to glucagon rescue therapies have continued to support the segment's dominant position.

The gastrointestinal disorders segment is expected to record the fastest growth as glucagon gains wider use in diagnostic and procedural settings requiring temporary relaxation of gastrointestinal smooth muscle. Growing utilization of advanced diagnostic imaging and endoscopic procedures, together with increased emphasis on improving procedural accuracy and patient outcomes, is contributing to the expanding adoption of glucagon in gastrointestinal applications.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Product Type	Injectable, Inhalation	Injectable	Inhalation
Distribution Channel	Hospital Pharmacies, Retail Pharmacies, Online Pharmacies	Hospital Pharmacies	Online Pharmacies
Application	Hypoglycemia, Diagnostic Aid, Gastrointestinal Disorders, Cardiogenic Shock, Others	Hypoglycemia	Gastrointestinal Disorders

Competitive Landscape and Market Positioning

Key companies in the glucagon market:

1. Eli Lilly and Company (United States)
2. Novo Nordisk A/S (Denmark)
3. Xeris Biopharma Holdings (United States)
4. Zealand Pharma A/S (Denmark)
5. Fresenius Kabi (Germany)
6. Amphastar Pharmaceuticals (United States)
7. Hanmi Pharmaceutical Co., Ltd. (South Korea)
8. Lupin Limited (India)
9. Sanofi (France)
10. Sandoz Group AG (Switzerland)

The glucagon market is moving toward a more differentiated competitive environment as suppliers focus on improving therapeutic accessibility, delivery convenience, and integration with evolving diabetes management approaches. Manufacturers are strengthening their positions through advancements in formulation strategies and patient-oriented delivery options, while specialized entrants are targeting unmet needs through more focused therapeutic developments. Competitive dynamics are increasingly shaped by the ability to enhance treatment experience, support broader clinical adoption, and align solutions with changing expectations among healthcare providers and patients.

Industry Development/News

Company Name	Date	Key Development
Eli Lilly	May-26	Eli Lilly expanded its manufacturing footprint in Indiana with an additional $4.5 billion investment. This capital injection is dedicated to scaling production capacity for tirzepatide, oral GLP-1 therapies, and genetic medicines, substantially reinforcing its competitive infrastructure to satisfy surging global demand for incretin-based therapeutics.
Boehringer Ingelheim	Apr-26	Boehringer Ingelheim disclosed positive Phase 3 SYNCHRONIZE-1 clinical data for survodutide, its dual glucagon/GLP-1 receptor agonist. The candidate demonstrated significant weight reduction over a 76-week period, validating its therapeutic efficacy and advancing the company's competitive positioning in the next-generation obesity market.
Eli Lilly	Feb-26	Eli Lilly expanded its long-term strategic collaboration with Innovent Biologics via a seventh R&D agreement valued at over $8.8 billion, including a $350 million upfront payment. This major financial commitment solidifies their joint development capabilities focused on advanced therapeutics for metabolic diseases.
Lupin Limited	Aug-25	Lupin Limited launched its generic Glucagon for Injection USP (1 mg/vial) emergency kit in the United States. Bioequivalent to Eli Lilly's reference product, this launch expands Lupin's critical diabetes-care injectables portfolio and introduces a competitive alternative for treating severe hypoglycemia.
Innovent Biologics	Jun-25	Innovent Biologics obtained a landmark first-in-class regulatory approval in China for mazdutide, a dual GLP-1/glucagon receptor agonist developed in partnership with Eli Lilly. The regulatory milestone marks a significant commercial entry into the regional obesity treatment market with a highly differentiated therapeutic mechanism.
Novo Nordisk	Mar-25	Novo Nordisk secured a licensing agreement valued at up to $2 billion to acquire the rights for UBT251, a novel triple agonist targeting GLP-1, GIP, and glucagon receptors. The acquisition strategically expands the company's clinical pipeline of next-generation obesity and metabolic disease treatments.
OPKO Health	Mar-25	OPKO Health formalized a strategic partnership with Entera Bio to advance the first oral dual GLP-1/glucagon receptor agonist into clinical development. The collaboration leverages specialized oral peptide platform technology to create differentiated, non-injectable treatment alternatives for the metabolic and obesity sectors.
Xeris Pharmaceuticals	May-24	Xeris Pharmaceuticals established an exclusive global collaboration with Beta Bionics to develop a dedicated glucagon product optimized for proprietary insulin pump technologies. This initiative drives commercial innovation in automated diabetes management by integrating specialized glucagon formulations directly into automated dual-hormone delivery systems.
WuXi STA	Apr-24	WuXi STA initiated a multi-site global facility expansion to significantly increase its peptide manufacturing capacity alongside advanced API and drug product infrastructure. This operational investment enhances global supply chain resilience and contract development capabilities to support the accelerating volume of peptide-based therapeutics.
Novo Holdings	Feb-24	Novo Holdings agreed to acquire Catalent for $16.5 billion in a strategic transaction designed to expand manufacturing capacity. The acquisition directly supports production scaling for Novo Nordisk's expanding portfolio of GLP-1 and obesity therapeutics, addressing global supply constraints within the high-growth metabolic disease market.